文献速递消化道肿瘤与早癌肝病

肝胆癌新靶点与新药研发进展

New targets and new drugs for hepatobiliary cancers.
PubMed 文献 · J Hepatol · 2025-08-25

综述总结肝胆癌药物研发两大方向:一是超越PD-1/CTLA-4的免疫新靶点、细胞治疗与双特异性T细胞衔接器;二是针对PPAR-α、KRAS、HDAC、β-catenin等传统难成药靶点的新策略,ADC亦在胆道癌中开发。

要点

  • 免疫治疗向新免疫检查点、细胞因子、CAR-T、TIL及双特异性T细胞衔接器拓展。
  • PPAR-α、KRAS、HDAC、β-catenin等难成药靶点迎来新策略。
  • 罕见肝脏肿瘤如肉瘤样HCC、混合型HCC-CCA可能对免疫检查点抑制剂有反应。

核心结论

  • 肝胆癌治疗正快速发展,新药研发可归为两类策略:靶向常规免疫检查点之外的免疫系统,以及攻克或重新设计传统难成药靶点。
  • 新兴证据显示上述两类疗法存在新的免疫调节作用,提示分类并非绝对。
  • 将肉瘤样HCC和混合型HCC-CCA等少见亚型纳入临床试验,可能加速有效治疗开发。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 靶向新免疫检查点及参与肿瘤免疫应答调控的细胞因子的抗体,其与已批准免疫治疗方案的联合正在II期和III期临床试验中探索。
  • 嵌合抗原受体T细胞和肿瘤浸润淋巴细胞等细胞疗法正在HCC和BTC的早期临床研究中测试。
  • 抗体工程进展已使双特异性T细胞衔接器的设计成为可能。
  • 针对PPAR-α、KRAS、HDAC和β-catenin等传统难成药靶点的新靶点或改良策略正在开发。
  • 表达HER2或nectin-4的抗体药物偶联物已在其他癌症中成功,现正针对BTC开发。

临床怎么用

  • 关注免疫新靶点抗体与已批准免疫方案联合的II/III期试验及细胞治疗早期研究。
  • 关注针对PPAR-α、KRAS、HDAC、β-catenin等难成药靶点的新策略及HER2/nectin-4 ADC在BTC中的开发。
  • 对肉瘤样HCC和混合型HCC-CCA等少见肝脏肿瘤,可考虑免疫检查点抑制剂并推动其进入临床试验。

局限性

  • 原文指出对上述进展的分类有些武断,因新兴证据揭示这些疗法具有新的免疫调节作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of hepatobiliary cancers has advanced rapidly, with novel approaches under active development. Current drug development can be classified into two primary strategies, based on their underlying mechanisms of action. The first focuses on novel therapies targeting the immune system beyond conventional immune checkpoints like programmed death-1 and cytotoxic T-lymphocyte-associated protein 4. This includes antibodies targeting new immune checkpoints and cytokines involved in tumour immune response regulation. Phase II and III clinical trials are exploring combinations of these antibodies with approved immunotherapy regimens. Cellular therapies, including chimeric antigen receptor-T cells and tumour-infiltrating lymphocytes, are also being tested in early clinical studies for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). Advances in antibody engineering have also enabled the design of bispecific T-cell engagers. The second direction addresses new targets or revised approaches to traditionally undruggable targets, such as peroxisome proliferator-activated receptor-α, Kirsten rat sarcoma viral oncogene, histone deacetylase, and β-catenin. Successful in other cancers, antibody-drug conjugates expressing human epidermal growth factor receptor-2 or nectin-4 are also being developed for BTC. Notably, the classification of these advances is somewhat arbitrary, as emerging evidence reveals new immunomodulatory roles for these therapies. Finally, these therapeutic advances suggest a change in the treatment approach for less common liver cancers, such as sarcomatoid HCC and combined HCC-cholangiocarcinoma. Recent clinical experiences and genomic data indicate potential responsiveness to immune checkpoint inhibitors. Including these subtypes in clinical trials may help accelerate the development of effective treatments for these uncommon entities.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chan SL, Lamarca A, Hsu C, et al. New targets and new drugs for hepatobiliary cancers. J Hepatol. 2025. PMID: 40865646. doi:10.1016/j.jhep.2025.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。